Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

EC approves Symtuza for HIV-1, Janssen submits NDA to FDA

Meghan Sullivan
October 27, 2017 7:05 PM UTC

Johnson & Johnson (NYSE:JNJ) said in September its Janssen Research & Development LLC unit submitted an NDA to FDA for a once-daily fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide to treat HIV-1 infection in patients ages 12 and older.

Also in September, the European Commission approved the combination under the name Symtuza to treat HIV-1 infection in patients ages 12 and older with a body weight of ≥40 kg...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.

Johnson & Johnson